HuGE Literature Finder
Records
1
-
11
Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20. Virchows Archiv : an international journal of pathology 2022 1 480 (3): 543-555. Lee Ji Ae, Seo Mi-Kyoung, Yoo Seung-Yeon, Cho Nam-Yun, Kwak Yoonjin, Lee Kyoungbun, Kim Jung Ho, Kang Gyeong Ho |
CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup. Frontiers in oncology 2020 3 10 8. Aasebø Kristine, Dragomir Anca, Sundström Magnus, Mezheyeuski Artur, Edqvist Per-Henrik, Eide Geir Egil, Ponten Fredrik, Pfeiffer Per, Glimelius Bengt, Sorbye Halfd |
The clinicopathological and molecular features of sporadic gastric foveolar type neoplasia. Virchows Archiv : an international journal of pathology 2020 6 477 (6): 835-844. Sugai Tamotsu, Uesugi Noriyuki, Habano Wataru, Sugimoto Ryo, Eizuka Makoto, Fujita Yasuko, Osakabe Mitsumasa, Toya Yosuke, Suzuki Hiromu, Matsumoto Takayu |
p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. British journal of cancer 2019 Mar . Oh Hyeon Jeong, Bae Jeong Mo, Wen Xianyu, Jung Seorin, Kim Younghoon, Kim Kyung Ju, Cho Nam-Yun, Kim Jung Ho, Han Sae-Won, Kim Tae-You, Kang Gyeong Ho |
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Molecular oncology 2018 6 12 (9): 1639-1655. Bruun Jarle, Sveen Anita, Barros Rita, Eide Peter W, Eilertsen Ina, Kolberg Matthias, Pellinen Teijo, David Leonor, Svindland Aud, Kallioniemi Olli, Guren Marianne G, Nesbakken Arild, Almeida Raquel, Lothe Ragnhild |
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Mar 24 (3): 693-701. Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, Di Gregorio C, Scardoni M, Amato E, Frizziero M, Sperduti I, Corbo V, Brunelli M, Bersani S, Tortora G, Scarpa |
Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. The American journal of surgical pathology 2012 2 36 (4): 601-11. La Rosa Stefano, Marando Alessandro, Furlan Daniela, Sahnane Nora, Capella Car |
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. International journal of cancer. Journal international du cancer 2010 Jul 127 (2): 367-80. Zlobec Inti, Bihl Michel P, Schwarb Heike, Terracciano Luigi, Lugli Alessand |
Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutation research 2009 Jan 660 (1-2): 12-21. Slattery Martha L, Wolff Roger K, Curtin Karen, Fitzpatrick Frank, Herrick Jennifer, Potter John D, Caan Bette J, Samowitz Wade |
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2009 7 15 (14): 4665-73. Baba Yoshifumi, Nosho Katsuhiko, Shima Kaori, Freed Ellen, Irahara Natsumi, Philips Juliet, Meyerhardt Jeffrey A, Hornick Jason L, Shivdasani Ramesh A, Fuchs Charles S, Ogino Shu |
CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer research 2005 Jul 65 (13): 5488-92. Rozek Laura S, Lipkin Steven M, Fearon Eric R, Hanash Samir, Giordano Thomas J, Greenson Joel K, Kuick Rork, Misek David E, Taylor Jeremy M G, Douglas Julie A, Rennert Gad, Gruber Stephen |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: